GSK blood cancer drug nearly halves risk of death in late-stage trial
By Pratik Jain (Reuters) – GSK’s multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday. In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% …
GSK blood cancer drug nearly halves risk of death in late-stage trial Read More »










